These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33184050)

  • 61. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
    Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation.
    Bueno De Paiva L; Aline Bernusso V; Machado-Neto JA; Traina F; Ridley AJ; Olalla-Saad ST; Lazarini M
    Small GTPases; 2021 Jan; 12(1):20-26. PubMed ID: 30449238
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
    Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
    Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
    Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
    BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Michael A; Ball G; Quatan N; Wushishi F; Russell N; Whelan J; Chakraborty P; Leader D; Whelan M; Pandha H
    Clin Cancer Res; 2005 Jun; 11(12):4469-78. PubMed ID: 15958632
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.
    Lubaroff DM; Konety BR; Link B; Gerstbrein J; Madsen T; Shannon M; Howard J; Paisley J; Boeglin D; Ratliff TL; Williams RD
    Clin Cancer Res; 2009 Dec; 15(23):7375-80. PubMed ID: 19920098
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
    Ishikawa H; Imano M; Shiraishi O; Yasuda A; Peng YF; Shinkai M; Yasuda T; Imamoto H; Shiozaki H
    Gastric Cancer; 2014 Jan; 17(1):173-80. PubMed ID: 23613128
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
    Hongo F; Ueda T; Takaha N; Tamada S; Nakatani T; Miki T; Ukimura O
    Int J Urol; 2023 Feb; 30(2):176-180. PubMed ID: 36305687
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
    Okamoto I; Arao T; Miyazaki M; Satoh T; Okamoto K; Tsunoda T; Nishio K; Nakagawa K
    Cancer Sci; 2012 Dec; 103(12):2135-8. PubMed ID: 22957712
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vaccination therapy in prostate cancer.
    Marrari A; Iero M; Pilla L; Villa S; Salvioni R; Valdagni R; Parmiani G; Rivoltini L
    Cancer Immunol Immunother; 2007 Apr; 56(4):429-45. PubMed ID: 17031640
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.
    Lu L; Yan H; Shyam-Sundar V; Janowitz T
    Drug Des Devel Ther; 2014; 8():1539-53. PubMed ID: 25302014
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Prostate carcinoma: vaccination as a new option for treatment].
    Bedke J; Gouttefangeas C; Stenzl A
    Urologe A; 2012 Jan; 51(1):44-9. PubMed ID: 21989588
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Spherical Nucleic Acid Vaccine Structure Markedly Influences Adaptive Immune Responses of Clinically Utilized Prostate Cancer Targets.
    Teplensky MH; Dittmar JW; Qin L; Wang S; Evangelopoulos M; Zhang B; Mirkin CA
    Adv Healthc Mater; 2021 Nov; 10(22):e2101262. PubMed ID: 34494382
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation.
    Zelba H; McQueeney A; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Harter J; Latzer P; Hadaschik D; Battke F; Hartkopf AD; Biskup S
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.